<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ABCIXIMAB <img border="0" src="../images/pr.gif"/></span><br/>(ab-cix<b>
<b>
<b>'</b>
</b>
</b>i-mab)<br/><span class="topboxtradename">ReoPro<br/></span><b>Classifications:</b> <span class="classification">blood formers and coagulants</span>; <span class="classification">antithrombotic</span>; <span class="classification">antiplatelet</span>; <span class="classification">glycoprotein iib/iiia inhibitor</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg/mL in 5 mL vials</p>
<h1><a name="action">Actions</a></h1>
<p>Abciximab is a humanmurine monoclonal antibody Fab (fragment antigen binding) fragment that binds to the glycoprotein
         IIb/IIIa (GPIIb/IIIa) receptor sites of platelets.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Abciximab inhibits platelet aggregation by preventing fibrinogen, von Willebrand's factor, and other molecules from adhering
         to GPIIb/IIIa receptor sites of the platelets.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to aspirin and heparin for the prevention of acute cardiac ischemic complications in patients undergoing percutaneous
         transluminal coronary angioplasty (PTCA).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to abciximab or to murine proteins; active internal bleeding; GI or GU bleeding within 6 wk; history of CVA
         within 2 y or a CVA with severe neurologic deficit; administration of oral anticoagulants unless PT 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C); lactation; patients weighing 70 min.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">PTCA</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> Starting 1060 min prior to start of angioplasty, 0.25 mg/kg bolus over 5 min followed by continuous infusion of 0.125
               mcg/kg/min (up to 10 mcg/min) for next 12 h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Do not shake vial. Discard if visible opaque particles are noted.</li>
<li>Use a nonpyrogenic low protein-binding 0.2- or 0.22-<img border="0" src="../images/special/mulower.gif"/>m filter when withdrawing
                     drug into a syringe from the 2 mg/mL vial and when infusing as continuous IV.
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> No dilution required.  <span class="methodtype">Continuous:</span> Inject 4.5 mL of drug into 250 mL of NS or D5W.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give undiluted bolus dose over 5 min.  <span class="methodtype">Continuous:</span> Infuse at no more than 17 mL/h (10 mcg/min) via an infusion pump; add no other drugs to the solution or IV line.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> Infuse through separate IV line. <span class="incompattype">Y-site:</span> Infuse through separate IV line. 
               </p>
<ul>
<li>Discard any unused drug at the end of the 12-h infusion as well as any unused portion left in vial.</li>
<li>Store vials at 2°8° C (36°46° F).</li>
</ul>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Hematologic:</span>
<span class="speceff-both">Bleeding</span>, including intracranial, retroperitoneal, and hematemesis; thrombocytopenia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">oral anticoagulants</span>, <span class="classification">nsaids</span>, <b>dipyridamole,</b>
<b>ticlopidine,</b>
<b>dextran</b> may increase risk of bleeding. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> &gt;90% inhibition of platelet aggregation within 2 h. <span class="typehead">Duration:</span> Approximately 48 h. <span class="typehead">Half-Life:</span> 30 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of: bleeding at all potential sites (e.g., catheter insertion, needle puncture, or cutdown sites; GI, GU,
            or retroperitoneal sites); hypersensitivity that may occur any time during administration.
         </li>
<li>Lab tests: Monitor Hgb, Hct, platelet count, PT, APTT, INR, and activated clotting time, every 24 h during first 24
            h.
         </li>
<li>Avoid or minimize unnecessary invasive procedures and devices to reduce risk of bleeding.</li>
<li>Elevate head of bed <img src="../images/special/lesserorequal.gif"/>30° and keep limb straight when femoral artery access
            is used; following sheath removal, apply pressure for 30 min.
         </li>
<li>Stop infusion immediately &amp; notify physician if bleeding or S&amp;S of hypersensitivity occurs.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any S&amp;S of bleeding immediately.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>